Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL) (NAUTICAL)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04574960 |
|
Recruitment Status :
Recruiting
First Posted : October 5, 2020
Last Update Posted : March 26, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Upper tract urothelial cancer (UTUC) is cancer in the lining of the kidney or ureter (the tube that drains the kidney). This type of cancer is rare and as a result, there are only a few studies that have looked at it.
Standard of care for UTUC would be surgery followed by chemotherapy (adjuvant chemotherapy). However, we know from studies that have looked at cancer of the lining of the bladder, which is a similar cancer in many ways, that treating people with chemotherapy before surgery (neoadjuvant chemotherapy) can lead to longer survival compared to the standard of care. There are no studies to show this in UTUC. Neoadjuvant chemotherapy is thought to help improve survival by treating any cancer that may have spread from the original tumour but that is not visible yet on scans. This study would be the first clinical trial in Canada to evaluate the use of chemotherapy before surgery in this disease setting.
Since UTUC is rare, the purpose of this study is to determine if it is possible to enrol enough patients to a trial looking at the use of chemotherapy before surgery.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Bladder Cancer Bladder Urothelial Carcinoma | Drug: Gemcitabine Drug: Cisplatin Drug: Carboplatin | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 14 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Neoadjuvant Chemotherapy in Upper Tract Urothelial Cancer: A Multicentre, Feasibility Pilot Trial |
| Actual Study Start Date : | February 8, 2021 |
| Estimated Primary Completion Date : | February 2022 |
| Estimated Study Completion Date : | February 2025 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Neoadjuvant Chemotherapy Arm
Gemcitabine/Cisplatin will be administered on a 3-week cycle for up to 4 cycles. This will be followed by surgical intervention (nephroureterectomy or ureterectomy).
|
Drug: Gemcitabine
Gemcitabine 1000 mg/m^2, IV infusion on days 1 and 8 of each 3-week cycle
Other Name: Gemzar Drug: Cisplatin Cisplatin 70 mg/m^2, IV infusion on day 1 of each 3-week cycle
Other Name: Platinol |
|
Active Comparator: Adjuvant Chemotherapy Arm (Standard of Care)
Patients will undergo surgical intervention (nephroureterectomy or ureterectomy) followed by adjuvant chemotherapy. Patients with a GFR greater or equal to 60 mL/min will receive Gemcitabine/Cisplatin while those with a GFR greater or equal to 30 mL/min but less than 60 mL/min will receive Gemcitabine/Carboplatin. Gemcitabine/Cisplatin will be administered on a 3-week cycle for up to 4 cycles. Gemcitabine/Carboplatin will be administered on a 3-week cycle for up to 4 cycles. |
Drug: Gemcitabine
Gemcitabine 1000 mg/m^2, IV infusion on days 1 and 8 of each 3-week cycle
Other Name: Gemzar Drug: Cisplatin Cisplatin 70 mg/m^2, IV infusion on day 1 of each 3-week cycle
Other Name: Platinol Drug: Carboplatin Carboplatin AUC 5-6 calculated using the Calvert formula on day 1 of each cycle
Other Name: Paraplatin |
- Feasibility of enrolling cT1-4N0 M0 UTUC patients in a randomized trial of neoadjuvant chemotherapy versus standard of care by assessing pilot trial recruitment rates [ Time Frame: 24 months ]
- Disease-free survival (DFS) [ Time Frame: 36 months ]DFS is defined as the time from randomization to development of intravesical recurrence, contralateral upper tract recurrence or distant metastasis
- Rate of complete pathologic response [ Time Frame: 36 months ]Complete pathologic response is defined as pT0 N0
- Site-specific enrolment rate [ Time Frame: 24 months ]
- Number of patients approached per site per month [ Time Frame: 24 months ]
- Number of patients randomized per site per month [ Time Frame: 24 months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Newly diagnosed radiographically visible (CT or MRI) cT1-4 N0 M0 with positive selective urinary cytology or endoscopic biopsy for high grade urothelial cell carcinoma
- Age ≥18 years of age
- Eastern Cooperative Oncology Group (ECOG) score 0-1
- Medically appropriate candidate for radical nephroureterectomy or ureterectomy as per participating site attending urologic oncologist
- Medically appropriate candidate for cisplatin-based chemotherapy as per participating site attending medical oncologist
- Adequate organ system function defined as follows: absolute neutrophil count ≥ 1500/mm3, platelets ≥ 100,00/mm3, hemoglobin ≥ 90 g/L, ALT and AST < 2.5 x upper limit of normal, electrolytes (Na, K, Mg, Ca): within normal limits, GFR ≥ 60 mL/min
Patients who are randomized to the adjuvant chemotherapy will be reassessed for suitability to receive adjuvant chemotherapy after definitive surgery (nephroureterectomy or ureterectomy) based on the following criteria:
- pT2-4 N0-3 M0 or pT any N1-3 M0 with predominant urothelial component
- ECOG score 0-2
- Medically appropriate candidate for platin-based chemotherapy as per participating site attending medical oncologist
- Adequate organ system function defined as follows: absolute neutrophil count ≥ 1500/mm3, platelets ≥ 100,00/mm3, hemoglobin ≥ 90 g/L, ALT and AST < 2.5 x upper limit of normal, electrolytes (Na, K, Mg, Ca): within normal limits, GFR ≥ 30 mL/min
Exclusion Criteria:
- Metastatic disease
- Radiographically visible nodal disease
- Concurrent muscle-invasive bladder cancer (non-muscle invasive bladder cancer is acceptable)
- Solitary kidney
- Other cancer diagnosis or systemic chemotherapy use within 2 years of study enrollment (prior bladder cancer and intravesical therapy allowed)
- Concomitant diseases that are a formal exclusion to cisplatin chemotherapy (deafness, ≥ grade II neuropathy, serious active infection)
- Concomitant use of any other investigational drugs
- Pregnancy or breast feeding (you must remain on contraception, not father a child or donate sperm while receiving gemcitabine/cisplatin and for 6 months following the last dose)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04574960
| Contact: Lena Sundaram | (416) 634-8219 | lena.sundaram2@uhn.ca | |
| Contact: Samantha Fung | 416-946-4501 ext 3897 | samantha.fung2@uhn.ca |
| Canada, Ontario | |
| University Health Network | Recruiting |
| Toronto, Ontario, Canada, M5G2M9 | |
| Contact: Sarah Cheung (437) 335-2949 sarah.cheung@uhn.ca | |
| Contact: Aisha Egal 416-946-4501 ext 3951 aisha.egal@uhnresearch.ca | |
| Principal Investigator: Girish Kulkarni, MD | |
| Principal Investigator: | Girish Kulkarni, MD | University Health Network - Princess Margaret Hospital |
| Responsible Party: | University Health Network, Toronto |
| ClinicalTrials.gov Identifier: | NCT04574960 |
| Other Study ID Numbers: |
20-5149 |
| First Posted: | October 5, 2020 Key Record Dates |
| Last Update Posted: | March 26, 2021 |
| Last Verified: | March 2021 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
|
Upper tract urothelial carcinoma UTUC |
|
Carcinoma, Transitional Cell Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Gemcitabine Cisplatin Carboplatin Antineoplastic Agents |
Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antiviral Agents Anti-Infective Agents Enzyme Inhibitors Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs |